Search: onr:"swepub:oai:lup.lub.lu.se:38cadbef-5a6d-4580-9c1d-1bcda92282df" > Predictive molecula...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05374naa a2200673 4500 | |
001 | oai:lup.lub.lu.se:38cadbef-5a6d-4580-9c1d-1bcda92282df | |
003 | SwePub | |
008 | 211118s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/38cadbef-5a6d-4580-9c1d-1bcda92282df2 URI |
024 | 7 | a https://doi.org/10.1136/jclinpath-2020-2069572 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Malapelle, Umbertou University of Naples Federico II4 aut |
245 | 1 0 | a Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe |
264 | c 2020-07-31 | |
264 | 1 | b BMJ,c 2021 |
300 | a 5 s. | |
520 | a Aims Lung cancer predictive biomarker testing is essential to select advanced-stage patients for targeted treatments and should be carried out without delays even during health emergencies, such as the coronavirus (COVID-19) outbreak. Methods Fifteen molecular laboratories from seven different European countries compared 4 weeks of national lockdown to a corresponding period in 2019, in terms of tissue and/or plasma-based molecular test workload, analytical platforms adopted, number of cases undergoing programmed death-ligand1 (PD-L1) expression assessment and DNA-based molecular tests turnaround time. Results In most laboratories (80.0%), tissue-based molecular test workload was reduced. In 40.0% of laboratories (6/15), the decrease was >25%, and in one, reduction was as high as 80.0%. In this instance, a concomitant increase in liquid biopsy was reported (60.0%). Remarkably, in 33.3% of the laboratories, real-time PCR (RT-PCR)-based methodologies increased, whereas highly multiplexing assays approaches decreased. Most laboratories (88.9%) did not report significant variations in PD-L1 volume testing. Conclusions The workload of molecular testing for patients with advanced-stage lung cancer during the lockdown showed little variations. Local strategies to overcome health emergency-related issues included the preference for RT-PCR tissue-based testing methodologies and, occasionally, for liquid biopsy. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
700 | 1 | a Pisapia, Pasqualeu University of Naples Federico II4 aut |
700 | 1 | a Iaccarino, Antoninou University of Naples Federico II4 aut |
700 | 1 | a Barberis, Massimou European Institute of Oncology4 aut |
700 | 1 | a Bellevicine, Claudiou University of Naples Federico II4 aut |
700 | 1 | a Brunnström, Hansu Lund University,Lunds universitet,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-hsb |
700 | 1 | a de Biase, Dariou University of Bologna4 aut |
700 | 1 | a de Maglio, Giovannau University Hospital of Udine4 aut |
700 | 1 | a Lindquist, Kajsa Ericsonu Lund University,Lunds universitet,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-ker |
700 | 1 | a Fassan, Matteou University of Padova4 aut |
700 | 1 | a Fontanini, Gabriellau University of Pisa4 aut |
700 | 1 | a Gruppioni, Elisau University of Bologna4 aut |
700 | 1 | a Hofman, Paulu Institut Gustave Roussy4 aut |
700 | 1 | a Merkelbach-Bruse, Sabineu University Hospital of Cologne4 aut |
700 | 1 | a Molina Vila, Miguel A.u Pangaea Oncology4 aut |
700 | 1 | a Pujals, Anaïsu Henri Mondor Hospital4 aut |
700 | 1 | a Rapa, Idau San Luigi University Hospital4 aut |
700 | 1 | a Righi, Luisellau University of Turin4 aut |
700 | 1 | a Rosell, Rafaelu Hospital Universitari Germans Trias i Pujol4 aut |
700 | 1 | a Schildgen, Oliveru Witten/Herdecke University4 aut |
700 | 1 | a Schildgen, Verenau Witten/Herdecke University4 aut |
700 | 1 | a Schmitt, Fernando C.u University of Porto4 aut |
700 | 1 | a Tallini, Giovanniu University of Bologna4 aut |
700 | 1 | a Borght, Sara Vanderu University Hospitals Leuven4 aut |
700 | 1 | a Vigliar, Elenau University of Naples Federico II4 aut |
700 | 1 | a Volante, Marcou University of Turin4 aut |
700 | 1 | a Wagener-Ryczek, Svenjau University Hospital of Cologne4 aut |
700 | 1 | a Weynand, Birgitu University Hospitals Leuven4 aut |
700 | 1 | a Troncone, Giancarlou University of Naples Federico II4 aut |
710 | 2 | a University of Naples Federico IIb European Institute of Oncology4 org |
773 | 0 | t Journal of Clinical Pathologyd : BMJg 74:6, s. 391-395q 74:6<391-395x 0021-9746x 1472-4146 |
856 | 4 | u http://dx.doi.org/10.1136/jclinpath-2020-206957y FULLTEXT |
856 | 4 | u https://jcp.bmj.com/content/jclinpath/74/6/391.full.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/38cadbef-5a6d-4580-9c1d-1bcda92282df |
856 | 4 8 | u https://doi.org/10.1136/jclinpath-2020-206957 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.